<DOC>
	<DOCNO>NCT00002880</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness etoposide treat patient relapse non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Etoposide Treating Patients With Relapsed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate response duration patient relapse non-Hodgkin 's lymphoma treat daily oral etoposide . II . Describe toxic effect daily oral etoposide patient . III . Monitor etoposide trough level determine whether etoposide concentration correlate age , response , toxicity . OUTLINE : Patients receive oral etoposide daily 21 day . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients complete partial remission receive 2 course past best response ( minimum 6 course ) . Patients stable disease 3 course may remove study . Patients follow every 6 month 2 year , annually survival . PROJECTED ACCRUAL : Approximately 97 patient accrue study 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document nonHodgkin 's lymphoma Needle core biopsy acceptable sole mean diagnosis No mantle cell transform lymphoma One follow International Working Formulation ( IWF ) histologic subtypes require : Small lymphocytic absolute lymphocytic count le 5,000 ( IWF A ) Follicular , predominately small cleave cell ( IWF B ) Follicular , mixed ( IWF C ) Follicular , large cell ( IWF D ) Diffuse , small cleave cell ( IWF E ) Diffuse , mixed ( IWF F ) Diffuse , large cell ( IWF G ) Large cell , immunoblastic ( IWF H ) Recurrent refractory disease treat 4 prior chemotherapy regimen Rebiopsy node first relapse recommend Prior etoposide ( oral intravenous ) allow give 5 day every 3 week The following consider 1 prior therapy : Identical drug give 2 different schedule Bone marrow transplant preparative regimen ( single cycle chemotherapy use solely mobilize peripheral blood stem cell consider part preparative regimen ) Ineligible protocol CLB9551 ( aminocamptothecin ) Measurable disease physical exam image study require Indicator lesion large 1 x 1 cm No prior radiotherapy indicator lesion unless progression clearly document The following consider measurable : Barium study Ascites pleural effusion Bony disease Bone marrow involvement No known parenchymal leptomeningeal CNS disease Lumbar puncture require prior study PATIENT CHARACTERISTICS : Age : Not specify Performance status : CALGB 02 Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal Renal : Creatinine great 1.5 time normal Other : HIV negative ( test require patient risk ) No uncontrolled infection No serious medical condition would interfere evaluation study agent No psychiatric condition would preclude protocol completion inform consent No second malignancy within 5 year except curatively treat : Basal cell skin cancer Cervical cancer Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 3 week nitrosoureas , melphalan , mitomycin ) Endocrine therapy : No concurrent corticosteroid except physiologic replacement Radiotherapy : At least 3 week since prior radiotherapy Surgery : Not specify Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
</DOC>